Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Change in Account Payables of -$990000.0 for Q1 2026, down 448.59% year-over-year from $284000.0 in Q1 2025, and down 193.93% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Change in Account Payables (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at -$990000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 448.59% year-over-year to -$990000.0; the TTM figure through Mar 2026 stood at -$793000.0 (up 49.23% YoY), while the FY2025 annual figure was $481000.0, up 119.43% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$990000.0, down from $1.1 million in the prior quarter.
- The five-year high for Change in Account Payables was $1.7 million in Q1 2023, with the low at -$1.4 million in Q2 2022.
- The 5-year median for Change in Account Payables is -$171000.0 (2023), against an average of -$30823.5.
- The sharpest annual moves came in 2022 and 2026: Change in Account Payables soared 847.62% in 2022, then plunged 448.59% in 2026.
- Foghorn Therapeutics' Change in Account Payables stood at $157000.0 in 2022, then plunged by 250.32% to -$236000.0 in 2023, then jumped by 241.53% to $334000.0 in 2024, then surged by 215.57% to $1.1 million in 2025, then slumped by 193.93% to -$990000.0 in 2026.
- Business Quant data shows FHTX's Change in Account Payables at -$990000.0 in Q1 2026, $1.1 million in Q4 2025, and -$110000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Foghorn Therapeutics | 347.75 Mn | 279.67 Mn | - | -69,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -69,000.00 |
| Mar 31, 2026 | -990,000.00 |
| Dec 31, 2025 | 1.05 Mn |
| Sep 30, 2025 | -110,000.00 |
| Jun 30, 2025 | -747,000.00 |
| Mar 31, 2025 | 284,000.00 |
| Dec 31, 2024 | 334,000.00 |
| Sep 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -829,000.00 |
| Mar 31, 2024 | -629,000.00 |
| Dec 31, 2023 | -236,000.00 |
| Sep 30, 2023 | -438,000.00 |
| Jun 30, 2023 | -171,000.00 |
| Mar 31, 2023 | 1.69 Mn |
| Dec 31, 2022 | 157,000.00 |
| Sep 30, 2022 | 1.62 Mn |
| Jun 30, 2022 | -1.44 Mn |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | -21,000.00 |
| Sep 30, 2021 | 415,000.00 |